Elutia (ELUT) Total Debt to Capital

Elutia Inc. (ELUT) - corporate logo

Bio-implant developer Elutia Inc. (ELUT) is facing logistical disruptions in Asia and international certification challenges. Simultaneously, the company is implementing AI-driven quality control and robotic CNC lines. This chart reflects a total debt-to-equity ratio of 0.70. While the business relies on sophisticated technologies, it faces risks from pressure by corporate behemoths and budget innovations in tissue engineering.

ELUT: elutia.com Debt to Equity Ratio 02/21/2024 - 10/29/2026

Analytical breakdowns for Elutia Inc.

- price and consensus price forecast:
Price Chart Elutia|ELUT - Consensus Target
- market capitalization details:
Market Capitalization Elutia|ELUT - Total Enterprise Value
- book capitalization indicators:
Book Value per Share Elutia|ELUT - Accounting Capitalization|Market Capitalization to Book Value Ratio elutia.com|ELUT - Company Total Asset Base
- issuer credit burden and liquidity indicators:
Total Debt to Capital Elutia Inc.|ELUT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Elutia Inc.|ELUT - Company Aggregate Debts|Debt to Book Capitalization Ratio Elutia|ELUT - Company Long-Term Debt|Company Current Liabilities Elutia|Quick Ratio elutia.com
- earnings and valuation multiples information:
ELUT - Net Financial Result
Basic company analysis:ELUT, Elutia
Finished products of Elutia Corporation

For Elutia Inc., a developer of high-tech bio-implants, a moderate debt load is critical for maintaining the pace of innovation and preserving the trust of the medical community. By analyzing the total debt-to-equity ratio, an investor assesses the proportion of borrowed capital within the financing structure, where a decrease in this ratio minimizes default risk and enhances the business's resilience to market shocks.

Key competitors

Debt to Equity Intuitive|Total Debt to Equity Ratio Danaher Corporation (DHR)|Total Debt to Capital BDX|STE - Debt to Capital|Total Debt to Capital WST (West Pharmaceutical Services)|BAX: Debt to Equity Ratio|Masimo - Total Debt to Capital|Total Debt to Capital Coefficient Stevanato Group SpA STVN|TFX: Total Debt to Capital|Total Debt to Equity Ratio Merit Medical Corp|NVST (Envista Holdings) - Total Debt to Capital|Total Debt to Capital icumed.com|Debt to Equity Dentsply Sirona (XRAY)|Debt to Equity LMAT (LeMaitre Vascular Inc)|AtriCure Corp - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio STAA|ChromaDex Corp. - Total Debt to Capital|Total Debt to Capital Coefficient zimvie.com ZIMV|AngioDynamics (ANGO) - Debt to Equity|Debt to Equity Ratio CERS|Debt to Equity Alpha Teknova Inc|Monogram Orthopedics Inc. (MGRM) - Total Debt to Capital Coefficient|Total Debt to Equity Ratio STSS (Sharps Technology, Inc.)|Aggregate Debt to Capital INFU|Debt to Equity Utah Medical Products, Inc. UTMD|All Debt to Shareholders' Equity Ratio KRMD|NYXH: Total Debt to Equity Ratio|MBOT - Total Debt to Capital|Pro-Dex, Inc. (PDEX) - Debt to Equity|Total Debt to Equity Ratio zentek.com|MLSS (Milestone Scientific Inc.) - Total Debt to Capital|Debt to Capital NEXGEL Inc. NXGL|Debt to Equity Retractable Technologies (RVP)|harvardbioscience.com - Debt to Equity Ratio|Femasys Inc. - Total Debt to Equity Ratio|Aggregate Debt to Capital MHUA (Meihua Medical Technologies)|POAI - Debt to Equity|Total Debt to Capital Coefficient Callan JMB Inc CJMB|ATRI: Total Debt to Capital|Debt to Capital NeuroMetrix Corporation (NURO)